Press releases 2010

Retiring as President and Chief Executive Officer of the DSM Pharmaceutical Products business group.

DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, is pleased to announce that their submission for the European Outsourcing Awards, organized by Via Media UK Ltd, entitled "Achieving substantial carbon dioxide footprint reduction for the scale up of a drug intermediate," was an award recipient at the 6th October ceremony held in Paris, France.

DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, is pleased to announce that their submission for the European Outsourcing Awards, organized by Via Media UK Ltd, entitled "Achieving substantial carbon dioxide footprint reduction for the scale up of a drug intermediate," was an award recipient at the 6th October ceremony held in Paris, France.

DSM BioSolutions today announced that it has entered into an agreement with Novacta Biosystems Limited, Welwyn Garden City, UK, for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.

DSM Biologics, a business unit of DSM Pharmaceutical Products, announced today advancement in its technology portfolio: a successful scale up of its proprietary, yield-boosting XD® technology from 2L to 50L using a CHO cell line. Rolf Douwenga, Vice President, Global Technology was quoted as saying: “We are excited about the robustness of the scale-up to 50L scale., The data proves again that the XD® technology is very consistent in scalability independent of the cell lines or types of recombinant proteins we have tested.”

DSM Biologics, a business unit of DSM Pharmaceutical products, today announced it has reached an agreement for the acquisition of the assets and associated business of the RHOBUST^® technology from Upfront Chromatography A/S (Denmark) for pharmaceutical and other applications.

DSM Biologics is pleased to announce the signing of preliminary agreements to enter a partnership with the Australian Governments to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.

DSM Pharmaceutical Products, based in Parsippany, NJ, today announced that it has received a Profiles in Sustainability award from United Business Media and ICIS Chemical Business.